New Medical Innovations

Transcript

Several new potential drug therapies for breast cancer have already emerged just in 2021.

One trial examined the effects of two drugs, nab-paclitaxel, and atezolizumab, which is immune therapy, and found that the combination led to increased survival rates among women with triple negative breast cancer. This is huge, because we usually just use cytotoxic chemotherapy with triple negative.

In a phase three study, the ASSET trial, they tested a drug called sacituzumab, which can lead to improved overall survival in women with metastatic triple negative breast cancer as well, who were receiving chemotherapy previously.

Key Takeaways

1. Several new potential drug therapies emerged in 2021.

2. One trial examined the effects of two immune therapy drugs, nab-paclitaxel, and atezolizumab that led to increased survival rates among women with triple negative breast cancer.

3. In a phase three study, the ASSET trial, they tested a drug called sacituzumab, which can lead to improved overall survival in women with metastatic triple negative breast cancer as well, who were receiving chemotherapy previously.